Despite the known risks of patients experiencing life-threatening side effects, prescribing standards vary widely among ...

There are glimmers of hope, however, with Eisai reporting last month that it is on track to meet that fiscal 2024 sales ...

With two years of experience selling Alzheimer’s disease antibody Leqembi so far under Eisai’s belt, the Japanese drugmaker ...

"Although there were some delays in the progression of sales results in the US, we believe that we are making a certain level of progress," it added. Longer-term, Eisai and Biogen are hoping for ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

Eisai to Divest Rights for Pariet in China to Peak Pharma TOKYO, Apr 1, 2025 - (JCN Newswire) - Eisai Co., ...

Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than in the US.

Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

The company's U.S. headquarters are in the ON3 complex in Nutley and Clifton. Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records ...

Future of Healthcategory· January 27, 2025 US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug The U.S. Food and Drug Administration has approved monthly maintenance dosing ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer the marketing authorisation approval decision of lecanemab in the ...